These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8739021)

  • 41. Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness.
    McPherson R; Hanna K; Agro A; Braeken A;
    Clin Ther; 2001 Sep; 23(9):1492-507. PubMed ID: 11589262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Double-masked comparison of the quality of life of hypercholesterolemic men treated with simvastatin or pravastatin. International Quality of Life Multicenter Group.
    Seed M; Weir MR
    Clin Ther; 1999 Oct; 21(10):1758-70. PubMed ID: 10566571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
    Carlsson CM; Papcke-Benson K; Carnes M; McBride PE; Stein JH
    Drugs Aging; 2002; 19(10):793-805. PubMed ID: 12390056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Pravastatin Multinational Study Group for Diabetes.
    Behounek BD; McGovern ME; Kassler-Taub KB; Markowitz JS; Bergman M
    Clin Cardiol; 1994 Oct; 17(10):558-62. PubMed ID: 8001304
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.
    Dujovne CA; Ettinger MP; McNeer JF; Lipka LJ; LeBeaut AP; Suresh R; Yang B; Veltri EP;
    Am J Cardiol; 2002 Nov; 90(10):1092-7. PubMed ID: 12423709
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pravastatin in the treatment of primary hypercholesterolemia: a Swiss multicenter study].
    Ferrari P; Weidmann P; Riesen WF; Martius F; Luban S; Pasotti E; Erne P; Fragiacomo C; Noseda G; Reutter F
    Schweiz Med Wochenschr; 1993 Sep; 123(37):1736-41. PubMed ID: 8211024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Double-dose pravastatin versus add-on ezetimibe with low-dose pravastatin - effects on LDL cholesterol, cholesterol absorption, and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study).
    Sasaki J; Otonari T; Sawayama Y; Hata S; Oshima Y; Saikawa T; Biro S; Kono S;
    J Atheroscler Thromb; 2012; 19(5):485-93. PubMed ID: 22659533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phytosterols dissolved in diacylglycerol oil reinforce the cholesterol-lowering effect of low-dose pravastatin treatment.
    Takeshita M; Katsuragi Y; Kusuhara M; Higashi K; Miyajima E; Mizuno K; Mori K; Obata T; Ohmori R; Ohsuzu F; Onodera Y; Sano J; Sawada S; Tabata S; Tokimitsu I; Tomonobu K; Yamashita T; Yasukawa T; Yonemura A; Nakamura H
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):483-91. PubMed ID: 17964767
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.
    Tsalamandris C; Panagiotopoulos S; Sinha A; Cooper ME; Jerums G
    J Cardiovasc Risk; 1994 Oct; 1(3):231-9. PubMed ID: 7621303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative efficacy of once-daily versus twice-daily pravastatin in primary hypercholesterolemia.
    Pan HY; DeVault AR; Brescia D; Willard DA
    Clin Ther; 1991; 13(3):368-72. PubMed ID: 1954638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome.
    Toto RD; Grundy SM; Vega GL
    Am J Nephrol; 2000; 20(1):12-7. PubMed ID: 10644862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia.
    Saunders E; Ferdinand K; Yellen LG; Tonkon MJ; Krug-Gourley S; Poland M
    J Natl Med Assoc; 2000 Jul; 92(7):319-26. PubMed ID: 10946527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
    Ballantyne CM; Houri J; Notarbartolo A; Melani L; Lipka LJ; Suresh R; Sun S; LeBeaut AP; Sager PT; Veltri EP;
    Circulation; 2003 May; 107(19):2409-15. PubMed ID: 12719279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study.
    Dujovne CA; Bays H; Davidson MH; Knopp R; Hunninghake DB; Stein EA; Goldberg AC; Jones P; Lipka LJ; Cuffie-Jackson C
    J Clin Pharmacol; 2001 Jan; 41(1):70-8. PubMed ID: 11144997
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluvastatin with and without niacin for hypercholesterolemia.
    Jacobson TA; Chin MM; Fromell GJ; Jokubaitis LA; Amorosa LF
    Am J Cardiol; 1994 Jul; 74(2):149-54. PubMed ID: 8023779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pravastatin in patients with cardiac risk factors. Effects of pravastatin in patients with total serum cholesterol concentrations of 200 to 300 mg/dl (5.2 to 7.8 mmol/l) and two additional atherosclerosis risk factors. Pravastatin Multinational Study Group for Cardiac Risk Patients].
    Fortschr Med; 1994 Feb; 112(5):57-64. PubMed ID: 8163252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.